BioSpace News Archive

Fate Therapeutics, Inc. (NASDAQ: FATE) today announced that two presentations will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.

Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, announced that it will present positive data from its program for Hepatitis B virus at the American Society of Gene & Cell Therapy 2024 Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland.

Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) is pleased to announce a non-brokered private placement financing (the “Offering”) of up 1,500,000 units of the Company (the “Units”) at a price of $0.40 per Unit, for aggregate gross proceeds of up to $600,000.

Genetic Technologies Limited announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares, each representing thirty ordinary shares of the Company, at an offering price of US$2.00 per ADS.

Legend Biotech Corporation announced today that the European Commission (EC) has granted approval of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), have demonstrated disease progression on the last therapy and are refractory to lenalidomide.

RxSight, Inc. announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024.

Cytonus Therapeutics, Inc., a biotherapeutic company developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes™, announced that Mickey Kim, M.D., M.B.A. has joined the company as Chief Business Officer.

Abeona Therapeutics Inc. announced a regulatory update for prademagene zamikeracel.

Biohaven Ltd. announced the closing of its underwritten public offering of 6,451,220 of its common shares, which includes the full exercise of the underwriters’ option to purchase 841,463 additional common shares, at a public offering price of $41.00 per share.

ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR) today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.